Live · Curated · High-Signal

The Signal

Hot news, developing stories, and the hidden forces high performers need to see first. Policy that moves markets. Molecules that move bodies. Systems that move minds. No noise... just what matters.

All ⚖️ Policy 📈 Markets 💪 Health 🤖 AI 🔧 Tech 🌐 Consciousness 🌎 Geopolitics
◆ Developing Story
Policy Health Developing July 23, 2026

FDA Advisory Panel Endorses Four Peptides for Compounding, Defying Staff Recommendation

After an 11-hour session, the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, and MOTS-c for the 503A Bulks List... over FDA staff's objection. Three more peptides face review Friday. Here is what happened, what did not, and what it means for anyone who cares about legal access to peptide therapy.

Read the full brief →
What The Panel Said
  • →BPC-157: Recommended 8-6-1
  • →KPV: Recommended 8-6-1
  • →TB-500: Recommended 8-6-1
  • →MOTS-c: Recommended ~7-5-2
  • →Day 2 (Jul 24): DSIP, Semax, Epitalon

Recent Signals

// Updated as things develop
Markets
JUL 25, 2026

The Trump Trade Is Bleeding Out

The Ned Davis Research Trump Trade Index has collapsed roughly 16% since May while the S&P 500 sits 2.7% off all-time highs. Capital is rotating out of policy-bet trades. What broke and what it means for positioning.

Full story →
Markets
JUL 25, 2026

Megacap Earnings Collide with the Fed This Week

Amazon, Meta, and Microsoft report earnings during the Fed meeting. Alphabet already stumbled on AI capex commentary. The 10-year is at 5%. The week that sets the H2 narrative.

Full story →
AI
JUL 25, 2026

Chinese AI Models Now Process 60% of US Business Tokens

Chinese open-weight models hold all five top spots by weekly volume on OpenRouter. Businesses route commodity workloads to the cheapest provider. The AI moat narrative is fracturing.

Full story →
Health
JUL 25, 2026

Lilly's $3.8B Psychedelics Acquisition Cracks Open a New Pharma Category

Eli Lilly acquired AtaiBeckley for $3.8 billion, the largest psychedelics deal in Big Pharma history. Psychedelic-assisted therapy crosses from fringe to institutional conviction.

Full story →
Health
JUL 25, 2026

First Oral PCSK9 Inhibitor Approved: The End of Cholesterol Injections Begins

Merck's Lipfendra is the first oral PCSK9 inhibitor. A daily pill replaces injections for the most powerful class of cholesterol drugs ever created. The accessibility equation changes.

Full story →
Policy
JUL 25, 2026

New Tariff Wave Hits 60 Countries Under Forced Labor Rationale

10-12.5% tariffs on 60 trading partners. The forced-labor framing is a legal workaround after courts struck down emergency-powers tariffs. The tariff wall is being rebuilt, not removed.

Full story →
Health Consciousness
JUL 25, 2026

Alzheimer's Sleep Loss Traced to Brain Immune Cells, Not Plaques

Researchers restored 2+ hours of NREM sleep in Alzheimer's models by depleting overactive microglia. The plaques were still there. The sleep came back. The paradigm is shifting.

Full story →
Policy Health
JUL 23, 2026 · DEVELOPING

FDA Peptide Advisory Panel: Day 1 Vote Overrides Staff Recommendation

The Pharmacy Compounding Advisory Committee endorsed four popular research peptides for the 503A Bulks List after an 11-hour session. What it means, what happens next.

Full story →
HealthMarkets
JUL 19, 2026 · DEEP READ

Retatrutide and the End of Metabolic Willpower

Lilly's triple agonist delivered 30.3% weight loss over 104 weeks in severe obesity. Bariatric outcomes without a scalpel. The science, the market, the meaning.

Read →

Get the Signal in your inbox

The most important thing that happened today, distilled. No filler. No spam. For high performers who read to move.

Subscribe to the Signal →